Cargando…

Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice

BACKGROUND: Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by selective degeneration of upper and lower motor neurons. The primary triggers for motor neuron degeneration are unknown but inflammation, oxidative stress and mitochondrial defects have been ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneb, Hannah M., Sharp, Paul S., Rahmani-Kondori, Nazanin, Wells, Dominic J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164704/
https://www.ncbi.nlm.nih.gov/pubmed/21909419
http://dx.doi.org/10.1371/journal.pone.0024189
_version_ 1782211075054239744
author Kaneb, Hannah M.
Sharp, Paul S.
Rahmani-Kondori, Nazanin
Wells, Dominic J.
author_facet Kaneb, Hannah M.
Sharp, Paul S.
Rahmani-Kondori, Nazanin
Wells, Dominic J.
author_sort Kaneb, Hannah M.
collection PubMed
description BACKGROUND: Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by selective degeneration of upper and lower motor neurons. The primary triggers for motor neuron degeneration are unknown but inflammation, oxidative stress and mitochondrial defects have been identified as potential contributing factors. Metformin is an anti-type II diabetes drug that has anti-inflammatory and anti-oxidant properties, can bring about mitochondrial biogenesis and has been shown to attenuate pathology in mouse models of Huntington's disease and multiple sclerosis. We therefore hypothesized that it might increase survival in the SOD1(G93A) murine model of ALS. METHODOLOGY/PRINCIPAL FINDINGS: Treatment of male and female SOD1(G93A) mice (n = ≥6 per sex) with 2 mg/ml metformin in the drinking water from 35 days, resulted in a significant increase in motor unit survival, as measured by in vivo electrophysiology at 100 days, in male EDL muscles (24+/−2 vs. 14+/−2 motor units, p<0.005) and female TA muscles (21+/−1 vs. 15+/−2 motor units, P = 0.0134). We therefore continued to test the effect of 0.5, 2 and 5 mg/ml metformin in the drinking water from 35 days on disease onset and progression (identified by twice weekly determination of weight and neurological score) as well as survival in male and female SOD1(G93A) mice (n = ≥14 per sex). Results for all groups were compared using Kaplan-Meier time to event analyses. In this survival study, metformin was unable to reduce pathology at any dose and had an unexpected dose-dependent negative effect on the onset of neurological symptoms (P = 0.0236) and on disease progression (P = 0.0362) in female mice. CONCLUSIONS/SIGNIFICANCE: This study suggests that metformin is a poor candidate for clinical trial in ALS patients and that the possibility of harmful effects of metformin in female ALS patients with type II diabetes should be investigated.
format Online
Article
Text
id pubmed-3164704
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31647042011-09-09 Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice Kaneb, Hannah M. Sharp, Paul S. Rahmani-Kondori, Nazanin Wells, Dominic J. PLoS One Research Article BACKGROUND: Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by selective degeneration of upper and lower motor neurons. The primary triggers for motor neuron degeneration are unknown but inflammation, oxidative stress and mitochondrial defects have been identified as potential contributing factors. Metformin is an anti-type II diabetes drug that has anti-inflammatory and anti-oxidant properties, can bring about mitochondrial biogenesis and has been shown to attenuate pathology in mouse models of Huntington's disease and multiple sclerosis. We therefore hypothesized that it might increase survival in the SOD1(G93A) murine model of ALS. METHODOLOGY/PRINCIPAL FINDINGS: Treatment of male and female SOD1(G93A) mice (n = ≥6 per sex) with 2 mg/ml metformin in the drinking water from 35 days, resulted in a significant increase in motor unit survival, as measured by in vivo electrophysiology at 100 days, in male EDL muscles (24+/−2 vs. 14+/−2 motor units, p<0.005) and female TA muscles (21+/−1 vs. 15+/−2 motor units, P = 0.0134). We therefore continued to test the effect of 0.5, 2 and 5 mg/ml metformin in the drinking water from 35 days on disease onset and progression (identified by twice weekly determination of weight and neurological score) as well as survival in male and female SOD1(G93A) mice (n = ≥14 per sex). Results for all groups were compared using Kaplan-Meier time to event analyses. In this survival study, metformin was unable to reduce pathology at any dose and had an unexpected dose-dependent negative effect on the onset of neurological symptoms (P = 0.0236) and on disease progression (P = 0.0362) in female mice. CONCLUSIONS/SIGNIFICANCE: This study suggests that metformin is a poor candidate for clinical trial in ALS patients and that the possibility of harmful effects of metformin in female ALS patients with type II diabetes should be investigated. Public Library of Science 2011-09-01 /pmc/articles/PMC3164704/ /pubmed/21909419 http://dx.doi.org/10.1371/journal.pone.0024189 Text en Kaneb et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kaneb, Hannah M.
Sharp, Paul S.
Rahmani-Kondori, Nazanin
Wells, Dominic J.
Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice
title Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice
title_full Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice
title_fullStr Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice
title_full_unstemmed Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice
title_short Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1(G93A) Mouse Model of ALS and Is Harmful in Female Mice
title_sort metformin treatment has no beneficial effect in a dose-response survival study in the sod1(g93a) mouse model of als and is harmful in female mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164704/
https://www.ncbi.nlm.nih.gov/pubmed/21909419
http://dx.doi.org/10.1371/journal.pone.0024189
work_keys_str_mv AT kanebhannahm metformintreatmenthasnobeneficialeffectinadoseresponsesurvivalstudyinthesod1g93amousemodelofalsandisharmfulinfemalemice
AT sharppauls metformintreatmenthasnobeneficialeffectinadoseresponsesurvivalstudyinthesod1g93amousemodelofalsandisharmfulinfemalemice
AT rahmanikondorinazanin metformintreatmenthasnobeneficialeffectinadoseresponsesurvivalstudyinthesod1g93amousemodelofalsandisharmfulinfemalemice
AT wellsdominicj metformintreatmenthasnobeneficialeffectinadoseresponsesurvivalstudyinthesod1g93amousemodelofalsandisharmfulinfemalemice